Filing summary: Signal Genetics, Inc. — Q3 2015 Form 10-Q
Entity mismatch: The supplied filing is for Signal Genetics, Inc., not Viridian Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2015; financial statements are unaudited. The filing describes a commercial-stage molecular diagnostics company selling its MyPRS multiple-myeloma test.
Financial performance and liquidity
| Metric | Three months ended September 30, 2015 | Nine months ended September 30, 2015 |
|---|---|---|
| Net revenue | $501,000; down 61% year over year | $1.879 million; down 49% |
| Cost of revenue | $577,000; 115% of revenue | $2.016 million; 107% of revenue |
| Gross result | $76,000 loss | $137,000 loss |
| Operating expenses | $3.629 million | $10.109 million |
| Operating loss | $3.128 million | $8.230 million |
| Net loss | $3.152 million; $0.39 per share | $8.348 million; $1.15 per share |
| Operating cash flow | Not provided for the quarter | $(5.599) million |
At September 30, cash and cash equivalents were $12.124 million, versus $5.119 million at December 31, 2014. Working capital was approximately $11.5 million; total current liabilities were $2.114 million. Cash increased by $7.005 million during the nine months, primarily due to $13.095 million of net stock-offering proceeds, partly offset by operating cash use. The company reported a $1.105 million related-party note, bearing 8% interest and payable on demand, and capital-lease obligations. No material capital-expenditure commitments were reported.
Changes versus comparable periods
- Third-quarter revenue fell $800,000 year over year. UAMS research-program revenue declined 92%, principally because UAMS had less funding. Management expected further declines from those programs.
- For the first nine months, revenue decreased $1.786 million. UAMS research-program revenue fell 63%; tests billed to other U.S. hospitals and direct-billed customers rose 60%, but revenue from that customer group was approximately flat.
- Contractual allowances rose to 62% of gross revenue in Q3 and 54% year to date, versus 31% and 26% in the respective 2014 periods. Management cited revised collection estimates, payer status and payment policies, and healthcare-industry changes.
- Sales and marketing expense increased sharply with expansion of the commercial and managed-care functions; research and development expense also increased. General and administrative expense rose modestly for the nine-month period.
- Net loss increased year over year, while nine-month interest expense declined to $118,000 from $1.021 million, primarily reflecting the prior-year debt conversion.
Outlook, risks and notable items
- Management forecast continued losses and negative operating cash flows, but expected available cash to fund operations for 12–15 months from the report date. It said additional financing or strategic investment may be needed; availability and terms are uncertain. Without funding, the company may have to reduce plans or discretionary spending.
- Management planned further investment in sales, marketing and R&D. It anticipated additional pharmaceutical-customer revenue, but provided no quantified revenue or earnings guidance.
- Reimbursement and collections are significant uncertainties. The company recorded $137,000 of unfavorable prior-period revenue estimate adjustments in the first nine months. It noted a potential additional $50,000 unfavorable adjustment if non-contracted payer collections on outstanding receivables followed a previously observed reduction pattern.
- UAMS-sourced revenue represented 64% of nine-month net revenue. One supplier provided inventory used in testing, creating supply-interruption risk. The filing also cites possible reimbursement pressure from healthcare policy changes, including PAMA and Medicare payment rules.
- In August, the company announced an agreement with America’s Choice Provider Network covering a reported 22 million patients. In October, it announced additional PPO agreements; these post-quarter arrangements were expected to increase network access, but the filing does not quantify realized revenue impact.
- The company reported no current legal proceedings. Management concluded disclosure controls were effective, but had not yet assessed internal control over financial reporting under the applicable newly public company rules.
Key facts for investors to verify
- Confirm the issuer: this filing is Signal Genetics, Inc., not Viridian Therapeutics, Inc.
- Track revenue quality and payer collections, especially the large contractual allowances, aged non-contracted receivables and prior-period estimate adjustments.
- Assess whether new payer-network and pharmaceutical agreements translate into collected revenue and reduce UAMS concentration.
- Monitor cash burn against the stated 12–15-month runway, and the availability and cost of future financing after completion of the ATM program.
- Review reimbursement changes under PAMA and other Medicare or commercial-payer policies, alongside the company’s ability to control operating expenses.